Palvella Therapeutics (PVLA) Curent Deferred Tax Liability (2013 - 2015)
Palvella Therapeutics (PVLA) posted quarterly Curent Deferred Tax Liability of $24464.0 for Q3 2015, little changed quarter-over-quarter from $24446.0 in Q2 2015.
Palvella Therapeutics (PVLA) Curent Deferred Tax Liability (2013 - 2015) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Curent Deferred Tax Liability for 3 consecutive years, with $24464.0 the latest figure, recorded in Q3 2015.
- In Q3 2015, Curent Deferred Tax Liability changed N/A year-over-year to $24464.0; the TTM figure through Sep 2015 stood at $24464.0 (changed N/A YoY), while the FY2014 annual figure was $26522.0, up 40.5% from the prior year.
- Curent Deferred Tax Liability held at $24464.0 in Q3 2015 per PVLA's latest filing, from $24446.0 in the prior quarter.
- Across five years, Curent Deferred Tax Liability topped out at $26522.0 in Q4 2014 and bottomed at $18877.0 in Q4 2013.
- Historically, Curent Deferred Tax Liability has averaged $23570.0 across 3 years, with a median of $24446.0 in 2015.
- On a YoY basis, Curent Deferred Tax Liability climbed as much as 40.5% in 2014 and fell as far as 40.5% in 2014.
- Palvella Therapeutics' Curent Deferred Tax Liability stood at $18877.0 in 2013, then jumped by 40.5% to $26522.0 in 2014, then decreased by 7.76% to $24464.0 in 2015.
- Business Quant data shows PVLA's Curent Deferred Tax Liability at $24464.0 in Q3 2015, $24446.0 in Q2 2015, and $23541.0 in Q1 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax Liability (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 24,464.00 |
| Sep 30, 2015 | 24,464.00 |
| Jun 30, 2015 | 24,446.00 |
| Jun 30, 2015 | 24,446.00 |
| Mar 31, 2015 | 23,541.00 |
| Mar 31, 2015 | 23,541.00 |
| Dec 31, 2014 | 26,522.00 |
| Dec 31, 2014 | 26,522.00 |
| Dec 31, 2013 | 18,877.00 |
| Dec 31, 2013 | 18,877.00 |